Higher versus lower dose corticosteroids for moderate to severe COVID-19: a systematic review, dose response and network meta-analysis.

T. Pitre (Hamilton, Canada), J. Mah (Halifax, Canada), W. Helmeczi (Ottawa, Canada), J. Su (Hamilton, Canada), S. Danhoe (Hamilton, Canada), W. Plaxton (Hamilton, Canada), S. Giilck (Hamilton, Canada), D. Zeraatkar (Harvard University, United States)

Source: International Congress 2022 – COVID-19 acute respiratory distress syndrome and beyond

Session: COVID-19 acute respiratory distress syndrome and beyond
Session type: Oral Presentation
Number: 2311

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
T. Pitre (Hamilton, Canada), J. Mah (Halifax, Canada), W. Helmeczi (Ottawa, Canada), J. Su (Hamilton, Canada), S. Danhoe (Hamilton, Canada), W. Plaxton (Hamilton, Canada), S. Giilck (Hamilton, Canada), D. Zeraatkar (Harvard University, United States). Higher versus lower dose corticosteroids for moderate to severe COVID-19: a systematic review, dose response and network meta-analysis.. 2311

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.